Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening (NCT04904757) | Clinical Trial Compass
RecruitingNot Applicable
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
United States210 participantsStarted 2019-09-19
Plain-language summary
The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.
Who can participate
Age range40 Years – 69 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* • Female
* 40 to 69 years
* Previous normal mammogram (BI-RADS 1 or 2) showing heterogeneous or extremely dense breast tissue within last 24 months
* Scheduled for screening mammogram as part of the patient's clinical care
Exclusion Criteria:
* • No mammogram within last 24 months
* Fatty or scattered fibroglandular tissue on last mammogram
* History of allergy to iodinated contrast
* History of renal disease or renal function abnormalities
* Pregnant women
* History of diabetes
* History of paraproteinemia syndromes such as multiple myeloma
* History of collagen vascular disease
* History of vascular disease (coronary artery disease, myocardial infarction, carotid disease, peripheral vascular disease, or known visceral artery disease)
* Previously identified as high risk for breast cancer (\>20% lifetime risk)
* Asthma
* Sickle Cell Anemia
* Currently on Dialysis
What they're measuring
1
Evaluate the patient experience during a screening CESM